The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Trial Profile

The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study'

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2017

At a glance

  • Drugs Afatinib (Primary) ; Esomeprazole (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Acronyms The BIO-GIO study
  • Most Recent Events

    • 21 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top